| Size | Price | Stock |
|---|---|---|
| 5mg | $435 | In-stock |
| 10mg | $695 | In-stock |
| 25mg | $1390 | In-stock |
| 50mg | $2220 | In-stock |
| 100mg | $3550 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-122830 |
| M.Wt: | 991.14 |
| Formula: | C55H62N10O8 |
| Purity: | >98 % |
| Solubility: | DMSO : 100 mg/mL (ultrasonic) |
DD-03-171 is a PROTAC BTK degrader. DD-03-171 inhibits mantle cell lymphoma (MCL) cell proliferation (IC50 = 5.1 nM) and prolongs the survival of mice bearing a lymphoma PDX model by degrading BTK, IKFZ1, and IKFZ3. DD-03-171 also inhibits platelet function and thrombosis. (Pink: BTK ligand 9 (HY-168292); Black: linker (HY-28875); Blue: Thalidomide-NH-CH2-COOH (HY-131717))[1][2][3].
IC50 & Target:IKFC[1]
In Vitro:DD-03-171 (1-10000 nM, 2-4 h) reduces cellular BTK levels in a proteasome- and CRBN-dependent manner in Ramos B cells[1].
DD-03-171 (40-1000 nM, 16 h) overcomes Ibrutinib (HY-10997) resistance and synergizes with HCK inhibition in ABC DLBCL in TMD8 ABC DLBCL cells[1].
DD-03-171 (100-1000 nM, 16 h) degrades IKZF1/3 and BTK, has antiproliferative effects on MCL cells (ED50 = 12 nM)
DD-03-171 (0-20 μM, 4-20 h) concentration-dependent degrades BTK in human platelets[2].
In Vivo:DD-03-171 (50 mg/kg, i.p., once a day, 3 days) induces degradation of BTK in c57BL/6 mice and NSG mice were engrafted with DFBL-18689/DFBL-39435/DFBL-39435/DFBL-44685/DFBL-98848 cells[1].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information
Your information is safe with us.